



(11) **EP 2 874 540 B1**

(12) **EUROPEAN PATENT SPECIFICATION**

(45) Date of publication and mention
of the grant of the patent:
12.09.2018 Bulletin 2018/37

(51) Int Cl.:
A61B 5/053 ^(2006.01) **A61M 1/16** ^(2006.01)
A61B 5/00 ^(2006.01)

(21) Application number: **13739614.9**

(86) International application number:
PCT/EP2013/002143

(22) Date of filing: **18.07.2013**

(87) International publication number:
WO 2014/012670 (23.01.2014 Gazette 2014/04)

(54) **CALIBRATION OF A BODY PARAMETER FOR MONITORING DIALYSIS**

KALIBRIERUNG EINES KÖRPERPARAMETERS ZUR DIALYSEÜBERWACHUNG

ÉTALONNAGE D'UN PARAMÈTRE CORPOREL POUR LE SUIVI D'UNE DIALYSE

(84) Designated Contracting States:
**AL AT BE BG CH CY CZ DE DK EE ES FI FR GB
GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO
PL PT RO RS SE SI SK SM TR**

(30) Priority: **19.07.2012 EP 12005286**

(43) Date of publication of application:
27.05.2015 Bulletin 2015/22

(73) Proprietor: **Fresenius Medical Care Deutschland
GmbH
61352 Bad Homburg (DE)**

(72) Inventors:
• **CHAMNEY, Paul
Tring
Hertfordshire HP23 4EW (GB)**
• **MOISSEL, Ulrich
61184 Karben (DE)**
• **WIESKOTTEN, Sebastian
64560 Erfelden (Riedstadt) (DE)**

(74) Representative: **Lindemann, Robert et al
Fresenius Medical Care AG & Co. KGaA
Global Intellectual Property
Else-Kröner-Straße 1
61352 Bad Homburg (DE)**

(56) References cited:
• **TITAPICCOLO J I ET AL: "Relative Blood Volume
Monitoring during hemodialysis in end stage
renal disease patients", 2010 ANNUAL
INTERNATIONAL CONFERENCE OF THE IEEE
ENGINEERING IN MEDICINE AND BIOLOGY
SOCIETY : (EMBC 2010) ; BUENOS AIRES,
ARGENTINA, 31 AUGUST - 4 SEPTEMBER 2010,
IEEE, PISCATAWAY, NJ, USA, 31 August 2010
(2010-08-31), pages 5282-5285, XP031883150,
DOI: 10.1109/IEMBS.2010.5626307 ISBN:
978-1-4244-4123-5**
• **MASATOMO YASHIRO ET AL: "Nature of the
filtration coefficients of the microvasculature in
the vicinity of dry weight in hemodialysis patients
- as a marker of the fluid status", COMPLEX
MEDICAL ENGINEERING (CME), 2012 ICME
INTERNATIONAL CONFERENCE ON, IEEE, 1 July
2012 (2012-07-01), pages 255-260, XP03222716,
DOI: 10.1109/ICCME.2012.6275629 ISBN:
978-1-4673-1617-0**
• **JUDITH J. DASSELAAR ET AL: "Effect of High
and Low Ultrafiltration Volume during
Hemodialysis on Relative Blood Volume", ASAIO
JOURNAL, vol. 52, no. 2, 1 March 2006
(2006-03-01), pages 169-173, XP55084056, ISSN:
1058-2916, DOI:
10.1097/01.mat.0000199896.27003.98**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

Description

[0001] The present disclosure concerns the calibration of a body parameter to the fluid status of an individual. The calibrated body parameter can subsequently be used as an indicator for the fluid status of the patient.

Background

[0002] Fluid status is an important issue in long-term dialysis patients and is related to clinical outcome. In fact, knowledge of a patient's fluid status is essential in efficiently managing hemo- as well as peritoneal-dialysis patients. Chronic fluid overload is associated with left ventricular hypertrophy, left ventricular dilatation, arterial hypertension, and eventually the development of congestive heart failure. High interdialytic weight gain on top of chronic fluid overload further increases the burden for the cardiovascular system. Recent studies have shown that fluid overload can even be linked to an increased mortality (Wizemann V. et al., "The mortality risk of overhydration in haemodialysis patients", Nephrol. Dial. Transplant 2009, 24:1574-1579). Management of the fluid status involves restriction of sodium intake and, to the extent possible and over time, attainment of a post-dialysis weight equal to the patient's dry weight or normohydration weight.

[0003] Normohydration weight is defined as the weight the patient would have with zero fluid overload. Fluid overload can be expressed as excess extracellular fluid volume (ECV). In order to have a comparative standard for a reference to body mass, body composition or total body water (TBW) is required.

[0004] In comparison, dry weight may be defined as the weight at which an individual is as close as possible to a normal fluid status without experiencing symptoms indicative of fluid overload or deficit. Clinically, dry weight is determined as the lowest weight a patient can tolerate without developing intra- or interdialytic symptoms of hypovolemia. This clinical assessment is hampered by the fact that some liters of fluid may accumulate in the body before an oedema becomes clinically evident and that it does not account for changes in lean body mass, fat mass or nutritional status over time. In addition, some patients may have symptoms on dialysis for heart problems that may not be related to fluid overload.

[0005] Therefore, normohydration and dry weight are closely linked with dry weight being slightly less than normohydration weight.

[0006] Several methods of determining the fluid status of an individual exist:

Isotope dilution methods are frequently recommended for fluid volume measurement (ECV or TBW), but they are clinically not feasible because of complexity and expense. Furthermore, these methods can determine the absolute quantities of ECV and TBW but cannot determine the amount of excess extracellular water (fluid overload) and thus no value for the normohydration weight.

[0007] Efforts have been made in the past to use the bioimpedance technology to facilitate the fluid reduction process. Cf., for example, Kuhlmann et al., "Bioimpedance, dry weight and blood pressure control: new methods and consequences", Current Opinion in Nephrology and Hypertension, 2005, 14:543-549, the disclosure of which is entirely incorporated by reference.

[0008] Several different bioimpedance approaches to determine the optimal fluid status have been published:

The normovolemic-hypervolemic slope method, cf., e.g. Chamney et al., "A new technique for establishing dry weight in hemodialysis patients via whole body bioimpedance", Kidney Int., 2002, 61:2250-2258, the disclosure of which is entirely incorporated by reference, applies whole body multi-frequency bioimpedance to assess pre-dialytic total body extracellular fluid volume and compares the extracellular fluid volume/body weight relation at hypervolemia with the standard value in normovolemic individuals.

[0009] The resistance-reactance graph method, cf., e.g. Piccoli et al., "A new method for monitoring body fluid variation by bioimpedance analysis: the RXc graph", Kidney Int., 1994, 46:534-539, the disclosure of which is entirely incorporated by reference, uses whole body single frequency bioimpedance for assessment of fluid status and nutritional status from height-adjusted resistance and reactance. The resulting resistance-reactance vector is set in relation to a distribution range in a normovolemic population. The difficulty of this method is that it does not provide absolute values of the fluid status - patients can only be compared to percentiles of a normal population.

[0010] Whole body bioimpedance spectroscopy (wBIS) is a noninvasive technique calculating the "whole body" extracellular fluid volume (wECV) and the whole body intracellular fluid volume (wICV) by measuring resistance and reactance over a range of alternating current frequencies (e.g. 50 to 250 frequencies from ca. 1 kHz to 1000kHz). Ratios of wECV or wICV to total body water volume (TBW) or the ratio wECV/wICV are used to assess the fluid status of a patient, cf., e.g. Wei Chen et al., "Extracellular Water/Intracellular Water Is a Strong Predictor of Patient Survival in Incident Peritoneal Dialysis Patients", Blood Purif., 2007, 25:260-266, the disclosure of which is entirely incorporated by reference.

[0011] The newest and more sophisticated technique is a whole body bioimpedance spectroscopy with a physiological tissue model: wECV and wTBW are measured by whole body bioimpedance spectroscopy and additionally the fluid

status and body composition are calculated. This is achieved by setting the measured patient in relation to a subject with a normal fluid status and the same body composition. Thus it relates back to the normohydrated properties of tissue. This physiologic tissue model is described in "A whole-body model to distinguish excess fluid from the hydration of major body tissues", Chamney P.W., Wabel P., Moissl U.M. et al., Am. J. Clin. Nutr., 2007, Jan, 85(1):80-9, the disclosure of which is entirely incorporated by reference. This method allows the patient specific prediction of the normal fluid status and the normal fluid status weight - the weight, the patient would have with a working kidney. This method also allows to determine the composition of the individual including adipose tissue mass (ATM or M_{AT}), lean tissue mass (LTM or M_{LT}) and extracellular water volume ECW .

[0012] An alternative method (see, for example, Zhu et al., "Adjustment of dry weight in hemodialysis patients using intradialytic continuous multifrequency bioimpedance of the calf", Int. J. Artif. Organs, 2004, 12:104-109 and Zhu et al., "A method for the estimation of hydration state during hemodialysis using a calf bioimpedance technique", Physiol. Meas., 2008: S503-S516, the disclosures of which are entirely incorporated by reference) uses segmental bioimpedance in the form of continuous intradialytic calf bioimpedance to record changes in calf extracellular volume during dialysis. Normohydration weight determined by this method is defined as the body weight at which calf extracellular volume is not further reduced despite ongoing ultrafiltration. Although this method is good for estimating normohydration of a patient, the technique requires the performance of bioimpedance measurements throughout a dialysis session. In fact, a prediction of the normohydration weight is not feasible at all. In addition, patient movement at the lower limb is limited during the dialysis session and measuring electrodes have to be kept in place until the session is finished.

[0013] Fluid management of individuals undergoing dialysis and/or ultrafiltration comprises three main steps: 1) the assessment of fluid status, 2) the optimisation of fluid status towards normohydration and 3) the maintenance of an "optimized" normohydration fluid status corresponding to the normohydration weight.

[0014] The above described methods cover the first step, and using a fluid reduction protocol as described in Petr Machek et. al.: "Guided optimization of fluid status in haemodialysis patients", Nephrol Dial Transplant (2010) 25: 538-544, which is incorporated by reference in its entirety provides a solution for the second step. Nevertheless, an urgent need exists to find a solution for maintaining the optimal fluid status.

[0015] This is particularly tricky, since one has to detect if an individual's weight alternates due to a change of fluid overload or due to a change in normohydration weight because of a change in bodycomposition (lean or fat mass).

[0016] Changes in normohydration weight can occur very quickly and may be overlooked in a lot of cases, leading to subsequent over- or underhydration over a longer period of time if the dialysis postweight, i.e. the weight after a dialysis, is not adjusted.

[0017] Therefore, either the fluid status and/or the normohydration weight should be updated regularly, at best in every treatment.

[0018] Unfortunately, the above described bioimpedance methods cannot be used in every treatment, but rather on a monthly basis or even just once every three months, in particular due to costs and/or to discomfort that these methods cause to the monitored individual.

[0019] Various other approaches to detect a change in the fluid status have been developed, such as blood volume monitoring, ultrasound assessment of inferior vena cava diameter and several biochemical parameters, such as brain or atrial natriuretic peptide.

[0020] In particular blood volume monitoring or plasma volume monitoring is believed to be a good indicator for detecting a change of fluid status or even to determine dry weight of an individual, cf., e.g. A.D. Sinha et al.: "Relative Plasma Volume Monitoring During Hemodialysis Aids the Assessment of Dry Weight", Hypertension. 2010; 55: 305-311, the disclosure of which is entirely incorporated by reference. Plasma volume monitoring assesses the balance between refilling and ultrafiltration rate in respect to the absolute plasma volume. Fluid overload is one of many factors influencing this relationship. Plasma is thereby directly linked to blood volume. Relative blood volume is a ratio of the blood volume at a certain moment compared to an earlier determined blood volume, e.g. at the beginning of a treatment session.

[0021] It has often been reported that flat relative blood volume curves are a sign of excessive fluid overload. According to Guyton, about 2/3 of fluid overload contribute to the interstitial space, and the remaining 1/3 contributes to the plasma volume, c.f. Guyton A.C. et al., "JE. Textbook of Medical Physiology", Philadelphia, W.B. Saunders, 2000, the disclosure of which is entirely incorporated by reference. Both effects result in a flatter relative blood volume curve: firstly, interstitial fluid overload provides a fluid reservoir that facilitates refilling from the interstitial to the vascular space. Secondly, a 1L decrease in plasma volume will lead to a smaller relative change if the absolute plasma volume is higher.

[0022] The article "Relative blood volume monitoring during Hemodialysis in end stage renal disease patients" by Tiapiccolo discloses a method for qualitative evaluation of the fluid status of a patient. None of these approaches, however, give an accurate estimate of the change of fluid status (overload/normohydration) due to the fact that they have not been proven to be practical or reliable in the determination in individual patients. Consequently, a majority of dialysis patients may be fluid overloaded or depleted without specific symptoms.

[0023] Therefore, there exists an urgent need to find an applicable parameter which can be determined cost-efficiently, easily and regularly without causing discomfort or even distress to the patient.

[0024] Furthermore, an urgent need for a determination of a change in fluid status and/or a fluid status and a treatment of an individual based on such a parameter exists, in particular to avoid unnoticed fluid overload or depletion in treated individuals. Put simply, it would be beneficial for the adequate fluid management of individuals to quantify fluid overload or even to be able to estimate dry weight and/or normohydration weight more reliably without causing discomfort to the individual than currently done in clinical practice.

Summary

[0025] The above-mentioned deficiencies in the art are addressed by apparatus claim 1 and computer-readable medium claim 14. Preferred embodiments are claimed in the depended claims.

[0026] In one embodiment, the present disclosure relates to a method for calibrating a body parameter of an individual comprising the steps of determining a change of the body parameter of the individual during a first treatment session, determining a first fluid status of the individual, and calibrating the determined change of the body parameter based on the first fluid status.

[0027] In one embodiment, the present disclosure relates to a method for detecting a change of the fluid status or determining the fluid status of an individual comprising the steps of determining a change of the body parameter of the individual during a first treatment session, determining a first fluid status of the individual, calibrating the determined change of the body parameter based on the first fluid status, determining the change of the body parameter of the individual during at least one further treatment session and deriving a fluid status or a change of fluid status of the individual from the change of the body parameter.

[0028] In one embodiment, the present disclosure relates to a method of bringing an initially fluid overloaded individual into its normal fluid status comprising the steps of determining a change of the body parameter of the individual during a treatment session, determining a first fluid status of the individual, calibrating the determined change of the body parameter based on the first fluid status, determining the change of the body parameter of the individual during at least one further treatment session and deriving an updated fluid status of the individual from the change of the body parameter and reducing the fluid overload of the individual based on the derived fluid status.

[0029] In one embodiment, the present disclosure relates to a method for calibrating a body parameter of an individual further comprising the step of determining a second change of a body parameter and/or a second fluid status during a second treatment session, wherein the calibration of the change of the body parameter is based on the first and second change of a body parameter and/or fluid statuses.

[0030] In one embodiment, the present disclosure relates to a method for calibrating a body parameter of an individual, wherein the body parameter is relative blood volume and/or the concentration of hemoglobin in the blood.

[0031] In one embodiment, the present disclosure relates to a method for calibrating a body parameter of an individual, wherein the treatment session is a dialysis and/or ultrafiltration treatment session.

[0032] In one embodiment, the present disclosure relates to a method for calibrating a body parameter of an individual further comprising a step of approximating the change of the body parameter by a polynomial regression, preferably of first order.

[0033] In one embodiment, the present disclosure relates to a method for calibrating a body parameter of an individual, wherein calibrating comprises the determination of at least one constant C and/ or a coefficient k of a polynomial.

[0034] In one embodiment, the present disclosure relates to a method for calibrating a body parameter of an individual, wherein the fluid status is determined by an assessment of a body composition of the individual.

[0035] In one embodiment, the present disclosure relates to a method for calibrating a body parameter of an individual, wherein the ultrafiltration rate is kept constant during the treatment sessions and/or among treatment sessions and/or the ultrafiltration volume is kept constant among treatment sessions.

[0036] In one embodiment, the present disclosure relates to a method for calibrating a body parameter of an individual further comprising normalizing the change of a body parameter by ultrafiltration volume, wherein calibrating the change of body parameter is based on this ratio.

[0037] In one embodiment, the present disclosure relates to a method for detecting a change of the fluid status or determining the fluid status of an individual further comprising the step of determining a second change of a body parameter and/or a second fluid status during a second treatment session, wherein the calibration of the change of the body parameter is based on the first and second change of a body parameter and/or fluid statuses.

[0038] In one embodiment, the present disclosure relates to a method for detecting a change of the fluid status or determining the fluid status of an individual, wherein the detected change of the fluid status and/or the determined fluid status is derived based on a polynomial regression, preferably of first order.

[0039] In one embodiment, the present disclosure relates to a method for determining a fluid status of an individual, wherein normohydration of the individual is reached, if the slope, in particular a slope of a polynomial regression of first order of the normalized change of the body parameter (ΔRBV) reaches a certain threshold.

[0040] In one embodiment the present disclosure relates to detecting a change of a fluid status wherein a change of

the relative blood volume during a succeeding treatment session is determined, wherein the step of detecting the change of the fluid status includes determining a first slope of the change of the relative blood volume during the further treatment session and determining a second slope of the change of the relative blood volume during the succeeding treatment session, wherein a difference between the first and the second slope is determined, and wherein a change of the fluid status is detected if the determined difference between the first and the second slope exceeds a predetermined threshold value.

[0041] The first and the second slope can be a linear slope or be determined by a non-linear fit.

[0042] The determined difference can be an absolute or a relative difference.

[0043] The predetermined threshold value may be between 5% and 15%, preferably between 8% and 12%, most preferably approximately 10%.

[0044] In one embodiment, the present disclosure relates to a method for detecting a change of the fluid status or determining the fluid status of an individual, wherein the change of fluid status triggers a new assessment of the body composition of an individual, preferably at the values used to determine the threshold.

[0045] In one embodiment, the present disclosure relates to a method of bringing an initially fluid overloaded individual into its normal fluid status further comprising a step of determining a second change of a body parameter and/or a second fluid status during a second treatment session, wherein the calibration of the change of the body parameter is based on the first and second change of a body parameter and/or fluid statuses.

[0046] In one embodiment, the present disclosure relates to an above method, wherein a first and/or second fluid status, an updated fluid status, a normal fluid status, a normohydration weight or any other data gained throughout a treatment session is transferred to a database via a data connection.

[0047] In one embodiment, the present disclosure relates to an above method, wherein the database is operated at a central server.

[0048] In one embodiment, the present disclosure relates to an above method, wherein the transferred data is processed such that statistics and/or conclusions for the treatment of the patient and/or a specific group of patients, in particular patients with comparable body parameters, may be derived.

[0049] In one embodiment, the present disclosure relates to an above method, wherein the fluid status and/or any other data gained throughout the treatment session is used to determine the dosage of a medicament, preferably of EPO, sodium and/or iron preparations.

[0050] In one embodiment, the present disclosure relates to an above method, wherein the fluid status is determined by bioimpedance spectroscopy of the individual.

[0051] In one embodiment, the present disclosure relates a medicament, preferably EPO, sodium and/or iron preparations, to be administered to a patient, wherein the dosage and/or the administration scheme of the medicament is determined based on the fluid status estimated according to a method of one of the above methods.

[0052] In one embodiment, the present disclosure relates to an apparatus, particularly with a memory and a digital signal processor, comprising a first determination unit configured to determine a change of a body parameter of the individual during a treatment session, a second determination unit to determine a first fluid status of the individual and a calibration unit to calibrate the determined change of the body parameter based on the first fluid status.

[0053] In one embodiment, the present disclosure relates to a computer program comprising instructions which, when being executed by a computer, cause the computer to execute an above method.

[0054] In one embodiment, the present disclosure relates to a computer-readable medium comprising instructions for the execution of an above method when the instructions are executed on a computer.

Brief description of the drawings

[0055]

Fig. 1 depicts a flow diagram of a method of calibrating a body parameter in accordance with the teachings of the present invention.

Fig. 2 depicts different intradialytic hemoglobin increase for one patient.

Fig. 3 depicts a flow diagram of a method for determining a fluid status or detecting a change of the fluid status in accordance with the teachings of the present invention.

Fig. 4 depicts a method of bringing an initially fluid overloaded individual into its normal fluid status in accordance with the teachings of the present invention.

Fig. 5 depicts an apparatus for calibrating a body parameter of an individual in accordance with the teachings of the

present invention.

Fig. 6 depicts a relationship between interstitial pressure and interstitial fluid volume

Fig. 7 depicts a dependency of bound fluid volumes in relation to overhydration

Fig. 8 depicts a dependency of blood volume BV in dependency of extracorporeal water ECW

Fig. 9 depicts a dependency between overhydration and relative blood volume variation rate

Fig. 10 depicts a stepped ultrafiltration profile

Detailed description

[0056] As discussed above, in various of its embodiments, the present disclosure relates to the problem of calibrating a body parameter of an individual. The individual will typically undergo hemodialysis, peritoneal dialysis or other forms of dialysis as a result of renal failure.

[0057] Nevertheless, the methods and apparatus disclosed herein can also be used to assess the fluid status and/or reduce the fluid overload of individuals suffering from renal failure or other, e.g., cardiac failure (also cardio-renal syndrome), liver failure, and/or chronic kidney disease which has not yet led to the need for dialysis treatment. For example, knowledge of the fluid status or dry weight can be of value with cardiac failure individuals who are being treated with diuretics to reduce their fluid volume. As in dialysis, knowledge of the individual's fluid overload is of clinical significance in deciding how much diuretic to prescribe.

[0058] In addition, the methods and apparatus can be used in connection with assessing the fluid status of normal individuals, e.g., individuals participating in strenuous activity under high temperature and/or high humidity conditions, e.g. athletes. More generally, knowledge of an individual's fluid status may be beneficial in terms of controlling the intake of, for example, sodium in the patient's diet, e.g., the patient (either an ill subject or a normal subject) can monitor his or her water retention as a result of sodium intake by comparing his or her weight to a fluid status determined in accordance with the present disclosure. Having information regarding fluid status may be of particular interest to fitness enthusiasts and other persons particularly concerned with their state of health.

[0059] The methods and apparatus disclosed herein will typically be employed at various points in time so that the calibration of a body parameter will be current with changes in the individual's body composition, e.g., changes in the individual's fat and/or muscle content as a result of diet and/or exercise or the lack thereof.

[0060] In the sense of the present disclosure, a body parameter is defined as a parameter characterizing the physical state of an individual. Examples for body parameters are heart rate, respiratory rate, blood pressure, blood volume, relative blood volume, inferior vena cava diameter, several biochemical parameters, such as brain or arterial natriotic peptide, body temperature, hemoglobin concentration, body weight, body volume, etc. and/or any combination thereof.

[0061] In the sense of the present disclosure, an individual is a human or an animal, in a healthy or ill condition.

[0062] In the sense of the present disclosure, a treatment session is defined as a unique, periodically or irregularly occurring treatment of an individual.

[0063] In the sense of the present disclosure, fluid status is the level of fluid in a body composition of an individual.

[0064] In the sense of the present disclosure, calibration is a comparison between measurements, one of known magnitude or correctness and another measurement, which magnitude or correctness is not known. The method of measurement with the known magnitude or correctness is called the standard. The second method of measurement is the calibrated method.

[0065] In the sense of the present disclosure, relative blood volume is the amount of blood volume in a second instance, compared to the amount of blood volume in a first instance, representing 100%. For example, a slope of relative blood volume may compare the blood volume during a dialysis treatment or ultrafiltration treatment session to the blood volume at the beginning of the treatment session. Relative blood volume is proportional to the relative plasma volume, such that one can be deduced from the other.

[0066] In the sense of the invention, a relative concentration of hemoglobin in the blood is the concentration of hemoglobin at a second instance compared to the concentration of haemoglobin in the blood at a first instance.

[0067] In the sense of the invention, normalising is the division or any other mathematical function of a parameter by a second parameter in order to limit or suppress the influence of the second parameter on the first parameter.

[0068] In the sense of the present disclosure, fluid overload means that the body of an individual comprises more fluid than in its normal fluid status corresponding to the normal fluid status weight, in particular a water excess or water intoxication.

[0069] In the sense of the present disclosure, dry weight is defined as the weight at which an individual is as close as

possible to a normohydration status or weight without experiencing symptoms indicative of fluid overload or deficit, if the fluid status of the patient is such that the patient is above the hypervolemic symptomatic weight.

[0070] In the sense of the present disclosure, a normohydration weight is the gender specific weight of a healthy individual.

[0071] In the sense of the present disclosure, reducing the fluid overload is the loss of body fluid having an influence on the fluid status of a patient.

[0072] In the sense of the present disclosure, intradialytic is defined as during a treatment session.

[0073] In the sense of the present disclosure, interdialytic is defined as between treatment sessions.

[0074] In the sense of the present disclosure, body composition comprises relevant parameters for the composition of an individual's body, such as total body water, interstitial water, extra cellular water, lean tissue mass, adipose tissue mass, bone mass, muscle mass, etc.

[0075] In the sense of the present disclosure, slope_{4h} is defined as the linear slope of the relative blood volume (RBV) over the full treatment normalized by the ultrafiltration rate (UFR).

[0076] According to the present disclosure, a body parameter of an individual is calibrated by the steps of determining a change of the body parameter of the body parameter (Δ RBV) of the individual during a first treatment session (101), determining a first fluid status of the individual (102) and calibrating the determined change of the body parameter (Δ RBV) based on the first fluid status (105).

[0077] By the means of the present invention, body parameters whose information on the physical condition of an individual is not completely known or understood can be calibrated individually for each individual based on the determined fluid status of the same. By this, the body parameter itself can serve in subsequent measurements as indicator for the physical condition of the individual, in particular for its fluid status.

[0078] The present invention therefore solves the problem that, even though body parameters could be used to find out the relative evolution of the fluid status, it was not possible to make a statement on the absolute value of the individual fluid status of an individual.

[0079] The fluid status of the individual may be determined before, after or during the treatment session and may comprise one or several determination points.

[0080] In a preferred embodiment a step of determining a second change of a body parameter (Δ RBV) and/or a second fluid status during a second treatment session (103), is accomplished, wherein the calibration of the change of the body parameter (Δ RBV) is based on the first and second change of a body parameter (Δ RBV) and/or fluid statuses.

[0081] By calibrating the body parameter on a first and second fluid status, the calibration of the body parameter is even more exact. In particular for predicting a fluid level based on a change of the body parameter (Δ RBV), the change in body parameter should be calibrated at two different fluid statuses. Based on these fluid levels, future fluid levels can be inter- or extrapolated.

[0082] In a further preferred embodiment the body parameter is relative blood volume (RBV), relative plasma volume and/or the concentration of hemoglobin in the blood.

[0083] As a particular advantage of the present invention body parameters which can be determined easily are used as the indicator for the physical condition of the patient, particularly his/her fluid status.

[0084] The above body parameters can be determined in a relatively simple manner. Measurement-techniques comprise photo-optical, electrical and chemical methods.

[0085] On the one hand the above body parameters are very convenient to measure, meaning that the examined individual does not have to suffer a limitation of its mobility and/or a physical distress and the sensors for measurement are cheap, reliable and robust.

[0086] On the other hand, the determination relies on equations which are easy to solve and give a robust result which is not volatile to small alterations of magnitude of the determined body parameter.

[0087] Another advantage of the present invention lies in the fact, that a correlation between a body parameter and the fluid status is introduced. This correlation permits to determine the fluid status without a genuine fluid status measurement and saves time and costs. Particularly, when the body parameter is a routinely and/or regularly checked parameter.

[0088] In a further preferred embodiment the change of the body parameter (Δ RBV) during the treatment is approximated by a polynomial regression.

[0089] By approximating the curve of the body parameter change, a continuous evolution of the discretely determined points can be determined, the resulting curve can be smoothened and/or a value for the slope of the curve can be determined, also as an average over the whole curve.

[0090] In a further preferred embodiment the ultrafiltration rate is kept constant during the treatment session and/or between treatment sessions and/or the body parameter (Δ RBV) is normalized by the ultrafiltration rate, wherein calibrating the change of body parameter (Δ RBV) is based on this ratio.

[0091] By these techniques, an influence of different ultrafiltration rates on the determination of the body parameter can be prevented.

[0092] According to the present disclosure, a fluid status of an individual is determined wherein a dry weight of the individual is reached, if the slope in particular a slope of a polynomial regression of first order of the normalized change of the body parameter (ΔRBV) reaches a certain threshold.

[0093] According to the present disclosure, a change of the fluid status is detected wherein the individual is treated during a treatment session succeeding the further treatment session and a change of the relative blood volume is determined during the succeeding treatment session. The step of detecting the change of the fluid status includes determining a first slope of the change of the relative blood volume during the further treatment session and determining a second slope of the change of the relative blood volume during the succeeding treatment session. A difference between the first and the second slope is determined, and a change of the fluid status is detected if the determined difference between the first and the second slope exceeds a predetermined threshold value.

[0094] The first and the second slope can be a linear slope or be determined by a non-linear fit.

[0095] The determined difference can be an absolute or a relative difference.

[0096] The predetermined threshold value may preferably be between 5% and 15%, more preferably between 8% and 12%, and most preferably approximately 10%.

[0097] In accordance with the teachings of the present invention, a reliable and simply to determine criterion is defined in order to determine the change of the fluid status.

[0098] Calibrating a body parameter of an individual is preferably based on a method as illustrated in Fig. 1. Merely by way of example, the calibration of a body parameter according to the present invention is demonstrated with respect to the relative blood volume (RBV) with the individual being a human patient being treated by ultrafiltration and/or dialysis. Nevertheless, as indicated above, the inventive methods can be applied to other body parameters and other forms of treatments.

[0099] In a first step of calibrating relative blood volume a change of the relative blood volume of the patient during a dialysis treatment session is determined (101). In a further step, which can be performed before, during or after the determination of the change of relative blood volume and thus before or after the dialysis treatment session, a first fluid status of the patient is determined (102). This is preferably performed by one of the methods described in the background section of the present patent application.

[0100] Preferably, the fluid status is determined by bioimpedance spectroscopy, even more preferably by a body composition monitoring with a Body Composition Monitor of Fresenius Medical Care®. In a another step of the inventive method, the determined change of the relative blood volume is calibrated based on the first fluid status (105). This means that a certain fluid status of the patient is assigned to a certain change of the relative blood volume (RBV), which is preferably represented by the slope of the timely evolution of the relative blood volume during a dialysis treatment session.

[0101] Figure 2 represents an intradialytic hemoglobin (Hb) increase in one patient at different fluid overload (FO) levels. The time span between the measurements was one month and the ultrafiltration volume (UFV) was kept constant at 3,3L in all three ultrafiltration treatments. At a high fluid overload (FO) of 3L, the slope of the hemoglobin (Hb) concentration curve is flatter than at a fluid overload of 1L. Hemoglobin (Hb) was determined by a blood volume monitoring (BVM), therefore it reflects an "inverse" relative blood volume (RBV).

[0102] By means of the invention, to every timely evolution of the relative blood volume (RBV) and/or the concentration of hemoglobin, i.e. a change of the body parameter, a fluid status can be assigned. For the changes of the relative blood volume with a flatter timely development, i.e. slope, one then knows that it represents a higher fluid overload whereas a steeper development of the change of relative blood volume (ΔRBV) represents a lower fluid overload or fluid status.

[0103] In one preferred embodiment, the inventive method comprises a step of determining a second change of a body parameter (ΔRBV) and/or a second fluid status during a second treatment session (103), wherein the calibration of the change of the body parameter (ΔRBV) is based on the first and second change of a body parameter (ΔRBV) and/or fluid statuses.

[0104] The calibration of the change of the relative blood volume (ΔRBV) is then based on the first and second fluid status. This allows for a more exact calibration of the relative blood volume (RBV) since two determined volumes of the fluid status exist to verify the corresponding change of relative blood volume (ΔRBV). Also, a calibration of a body parameter such as the change of relative blood volume (ΔRBV). in at least two different treatment sessions at different fluid statuses allows for a deduction of the fluid status in a further determination of relative blood volume (ΔRBV), which will be explained in more detail below.

[0105] In order to be able to draw a better comparison between the determined change of the relative blood volume (ΔRBV) and the determined fluid status or statuses, the evolution of the change of the relative blood volume (ΔRBV) is approximated by polynomial regression in a further step (104). In fact, a polynomial regression enhances the reproducibility of the determination of the change of the relative blood volume (ΔRBV).

[0106] Both, the steps of the second determination as well as of the polynomial regression are optional which is represented by the dashed flashes in the figures. To enhance the comparability of results the change of the body volume parameter (RBV) is normalized by the ultra filtration volume and/or the other filtration rate applied (106). More preferably, slope_{4h} defined as the linear slope of the relative blood volume (RBV) over the full treatment normalized by the ultrafil-

tration rate (UFR) is used. One way to accomplish normalization is to simply divide the determined change of relative blood volume (ΔRBV) by the value of the ultrafiltration volume (UFV) and/or the ultra filtration rate (UFR), respectively. In fact, confidence intervals were found to be extraordinarily high for a normalized slope, e.g. slope4h.

[0107] In Figure 3, a flow diagram for a determination of the fluid status and a detection of a change of the fluid status of an individual according to a method in accordance with the teachings of the present invention is described.

[0108] This method can be combined with the method of calibrating a body parameter as described in the foregoing.

[0109] In a first step of this method (201), a change of the relative blood volume (ΔRBV) is determined during a first treatment session. In a further step, a first fluid status of the patient is determined (202). In a third step, the calibration of the determined change of the relative blood volume (ΔRBV) based on the first fluid status is accomplished (205).

[0110] According to a preferred embodiment, in a further step a second change of a body parameter (ΔRBV) and/or a second fluid status during a second treatment session (203) is determined, respectively. The calibration of the change of the body parameter (ΔRBV) is subsequently based on the first and second change of a body parameter (ΔRBV) and the first and second fluid statuses.

[0111] Furthermore according to preferred embodiments of this inventive method, the change of the relative blood volume (ΔRBV) can be approximated by polynomial regression which can then preferably be used to determine the slope of the timely evolution of the change of relative blood volume (ΔRBV) during a dialysis treatment session (204) and/or the change of the relative blood volume (206) can be normalized.

[0112] In yet another step, the change of the relative blood volume (ΔRBV) is determined during at least one further treatment session (207). With this information at hand, the fluid status or a change of the fluid status can be derived from the change of the body parameter, here the relative blood volume (ΔRBV) or the hemoglobin concentration, in a further step (208).

[0113] This can be achieved using the formalism described in the ANNEX.

[0114] According to this method, the calibrated change of relative blood volume (ΔRBV) is used to deduce the fluid status or a change of the fluid status. A genuine measurement of the fluid status to detect a change, e.g. by bioimpedance spectroscopy, can be replaced. The relative blood volume (RBV) becomes therefore a marker for changes in the fluid status of a patient.

[0115] As mentioned above, this marker is not limited to the relative blood volume (RBV). For example, the above method may also be applied to the change of hemoglobin concentration in the blood of an individual.

[0116] In another preferred embodiment of this method, the detected change of fluid status serves as a trigger to induce an assessment of the body composition of an individual (209). By this, situations in which a patient becomes severely overhydrated or depleted without a weight change can be inhibited.

[0117] According to preferred embodiments, a trigger may be set as follows.

[0118] The individual is treated during a treatment session succeeding the further treatment session and a change of the relative blood volume is determined during the succeeding treatment session. The step of detecting the change of the fluid status includes determining a first slope of the change of the relative blood volume during the further treatment session and determining a second slope of the change of the relative blood volume during the succeeding treatment session. A difference between the first and the second slope is determined, and a change of the fluid status is detected if the determined difference between the first and the second slope exceeds a predetermined threshold value.

[0119] The predetermined threshold value may preferably be between 5% and 15%, more preferably between 8% and 12%, and most preferably approximately 10%. The thus detected change of the fluid status then serves as a trigger to induce to induce an assessment of the body composition of an individual (209).

[0120] By the determined change of the relative blood volume (ΔRBV), in addition to having a marker for when the fluid status of a patient changes, the fluid overload can be directly deducted from the measured values: alternatively to deriving a change of the fluid status from the change of the body parameter in step (208), the actual value for the fluid overload (FO) may be derived.

[0121] In a simple way this may be performed by just knowing that the above mentioned slopes correspond to a discrete value for the fluid status of an individual.

[0122] Alternatively, continuous values for the fluid status may be derived from the change of the body parameter, here the change of the relative blood volume (ΔRBV) or hemoglobin concentration. This can be achieved by using the formalism described in the ANNEX.

[0123] One might, in a preferred embodiment of the inventive method, deduce a limit for the change of the relative blood volume (ΔRBV) where the dry weight of the patient is reached. Ultrafiltration can then be immediately reduced to a lower level to avoid intradialytic symptoms of the patient.

[0124] A further method in accordance with the teachings of the present invention is demonstrated in Figure 4.

[0125] This method can be combined with the method of calibrating a body parameter and/or a method for detecting a change of the fluid status or determining a fluid status as described in the foregoing.

[0126] The further inventive method brings an initially fluid overloaded individual into its normal fluid status. Basically, this method uses the method to determine a fluid status or detect a change of the fluid status (steps 301 to 308) and

then reduces the fluid overload of the patient based on the fluid status (309). By this, intra-dialytic symptoms can be prevented since, due to the knowledge of the fluid status of the patient, the ultrafiltration rate (UFR) or volume (UFV) can already be controlled before the beginning of the treatment session in order to avoid such symptoms. In a preferred embodiment, the fluid status can be predicted by the equations, presented in relation with the method to determine a fluid status described in the ANNEX.

[0127] The fluid status may also be controlled "online", since from the slope of the body parameter at the beginning of the treatment session, preferably the first 50 or 100 minutes, a fluid status which will be reached during the treatment session can be deduced.

[0128] Figure 5 represents an apparatus (400) to accomplish the methods described above. In this figure, an individual, here a human patient, is dialyzed by a dialyzer 408. The blood of the patient is transported through the dialyzing lines (501, 502) to and from the dialyzer.

[0129] The apparatus (400) comprises a first determination unit (401) to determine a change of a body parameter, in this example the relative blood volume (ΔRBV) or hemoglobin concentration of the patient during a dialysis treatment session. The change of the body parameter may be determined with a sensor directly at the body of the patient or by a measuring unit (402) on samples of the blood flow of the blood lines (501, 502) of the dialyzer (500). Therefore, a determination does not imply a measurement on the body of the patient.

[0130] The acquired data is then preferably processed by a first processing unit (403) and provided to a calibration unit (406).

[0131] The fluid status of a patient is determined by a measuring unit (404), preferably by bioimpedance spectroscopy, in this example by whole body bioimpedance spectroscopy on the wrist and ankle of a patient. In a particularly preferred embodiment a BCM - Body Composition Monitor device of Fresenius Medical Care® is used to determine the body composition of the patient and to derive the fluid status from his/her body composition.

[0132] Preferably, this data is also processed by a second processing unit (405) and provided to the calibration unit (406). The calibration unit is adapted to perform the method of calibrating a body parameter of an individual according to the present invention.

[0133] In a preferred embodiment, the apparatus (400) further comprises a determination unit (407) to detect a change of the fluid status and/or to determine a fluid status. In a further preferred embodiment, the apparatus (400) comprises a control unit (408) to control the dialyzer (500), in particular the ultrafiltration rate (UFR) or the ultrafiltration volume (UFV) and therefore to control the reduction of the fluid overload by the dialyzer (500) based on the determined fluid status and/or the detected change of the fluid status, respectively.

[0134] The data in order to perform the control may be provided by the calibration unit and/or the determination unit as indicated by the connections in the schema of Fig. 5.

[0135] In a preferred embodiment, at a certain change of the fluid of the body parameter (e.g. relative blood volume (ΔRBV)) and therefore of the fluid status the control unit triggers an assessment of the body composition of the patient with the second measuring unit (404) or another unit (not represented).

[0136] The apparatus (400) is preferably an ordinary personal computer, a tablet PC or similar and all the units are preferably realized in just one processor and one memory (not illustrated).

ANNEX

[0137] The purpose of this ANNEX is to develop a relationship between blood volume and overhydration that could be exploited using measured variables that can be readily obtained during treatment, in particular during a dialysis and/or ultrafiltration treatment session. Consequently this allows several applications to be developed involving BVM and BCM. One of the key steps is to make use of the tissue hydration constants (body composition information) to obtain values of the extracellular water volume at normohydration ECW_{Norm} and the blood volume at normohydration BV_{Norm} . This ANNEX covers all the details necessary to arrive at the following expressions which are the key link between BCM and BVM.

[0138] At any time during treatment the following relationship holds (parameters not introduced already will be introduced in this ANNEX):

$$\begin{aligned} \dot{R} \cdot BV_{Norm} + \dot{R} \cdot f_n(OH(0)) + Q_{UFR}(t) \\ = [ECW_{Norm} + OH(0) - V_u(t) - RBV(t) \cdot (ECW_{Norm} + OH(0))] \cdot k_r \end{aligned}$$

$\dot{R}$ being the time derivative of the blood volume or blood volume slope, $d(RBV)/dt$.

[0139] As will be explained further below, at $t=0+$ (immediately after the start of treatment) the overhydration may be determined as follows

$$OH(0) = \frac{-1}{\lambda} \cdot \ln \left(\frac{Q_{ufr}(0^+) + \dot{R}(0^+) \cdot BV_{Norm}}{\dot{R}(0^+) \cdot \beta \cdot \delta V_{i_Gel_max}} \right) \forall OH \geq 0$$

$$OH(0) = \frac{-Q_{ufr}(0^+) - \dot{R} \cdot BV_{Norm}}{\dot{R} \cdot \alpha \cdot \beta} \forall OH < 0$$

Normal values of ECW and BV at zero overhydration

[0140] Typical values of extracellular water, ECW_{Norm} and blood volume, BV_{Norm} and other parameters used in this ANNEX are provided by the references and by Table 1.

Table 1 Reference values to obtain ECW_{Norm} and BV_{Norm}

Variable	Description	Value	Source
M_{WB}	Whole body weight	73 kg	Ref 1
M_{fat}	Mass of fat (non-essential lipid)	14.6 kg	Ref 1
H_{tw_AT}	Total hydration of adipose tissue	0.197	Ref 2
K_{ar}	Adipose tissue residual mass fraction	0.05	Ref 2
M_{AT}	Mass of adipose tissue	19.4	Eq. 1
M_{LT}	Mass of lean tissue	53.6	Eq. 2
H_{ecw_AT}	Hydration mass fraction of normally hydrated adipose tissue	0.127	Ref 2
H_{ecw_LT}	Hydration mass fraction of normally hydrated adipose tissue	0.266	Ref 2
ECW_{Norm}	Normally hydrated extracellular water	16.7 L	Eq. 3
BV_{Norm}	Normal blood volume	5.6 L	Eq. 4

[0141] Background knowledge on the subject matter is disclosed in references Ref. 1, Ref. 2 and Ref. 3, the entire content of which is hereby incorporated by reference.

Ref 1: Chamney PW, Wabel P, Moissl UM et al. A whole-body model to distinguish excess fluid from the hydration of major body tissues. Am J Clin Nutr 2007; 85: 80-89

Ref 2: ICRP. Basic anatomical and physiological data for use in radiological protection: reference values. ICRP Publication 89. Ann ICRP 2002;32:5-265.

Ref 3: Guyton AC. Medical Textbook of Physiology, 1991

$$M_{AT} = \frac{M_{Lipid}}{(1 - H_{tw_AT} - K_{ar})}$$

Eq. 1

M_{Lipid} being the lipid mass.

$$M_{LT} = M_{WB} - M_{AT}$$

Eq. 2

$$ECW_{Norm} = H_{ecw_LT} \cdot LTM + H_{ecw_AT} \cdot ATM$$

Eq. 3

$$BV_{Norm} = 0.1 \cdot LTM + 0.01 \cdot ATM$$

Eq. 4

Effects of overhydration on ECW and BV

[0142] The interstitial space has the well known relationship depicted in in Figure 6.

[0143] Adapted from Guyton (Ref 3). Note 2L of gel expansion as subject becomes overhy-drated.

[0144] The excess bound volume in interstitial and blood volume compartments caused by overhydration is depicted in Figure 7., the lower line indicating the portion of the bound overhydration associated with the blood volume, the middle line indicating the overhydration associated with the Gel compartment, and the upper line indicating the total bound fluid OH_{bound} .

[0145] The free fluid OH_{free} is the difference between the identity line corresponding to the total mass of the overhy-dration OH_{total} and the total bound fluid OH_{bound} , ie.

$$OH_{total} = OH_{bound} + OH_{free}$$

Interstitial volume relationships

[0146] At zero overhydration, using reference data, the ratio of normal interstitial volume $V_{i_Gel_Norm}$ to normal extra-cellular water ECW_{Norm} is :

$$\frac{V_{i_Gel_Norm}}{ECW_{Norm}} = \alpha = \frac{ECW_{Norm} - BV_{Norm}}{ECW_{Norm}}$$

Eq. 5

α being a proportionality constant.

[0147] If reference values for $V_{i_Gel_Norm}$ and ECW_{Norm} are substituted into Eq. 5, then $\alpha=0.671$. α can be calculated from Eq. 5 substituting values from Eq. 3 and Eq. 4

[0148] Where negative overhydration occurs the interstitial volume is linearly dependent on the extracellular water volume ECW or overhydration OH, i.e.

$$V_{i_Gel}(0) = \alpha \cdot ECW(0) = V_{i_Gel_Norm} + \alpha \cdot OH(0) \quad \forall \quad OH < 0$$

Eq. 6

V_{i_Gel} being the volume of the interstitial or Gel compartment and the index Norm indicating values at Normohydration

[0149] The expansion of the interstitial space (the gel) as a subject becomes overhydrated could be approximated by a simple exponential function:

$$\delta V_{i_Gel}(0) = \delta V_{i_Gel_max} \cdot (1 - e^{-\lambda \cdot OH(0)}) \quad \forall \quad OH(0) \geq 0$$

Eq. 7

λ being a proportionality constant.

[0150] At zero overhydration the gradient of Eq. 7 must be equal to α . In other words

$$\frac{V_{i_Gel_Norm}}{ECW_{Norm}} = \alpha = \delta V_{i_Gel_max} \cdot \lambda \cdot e^{-\lambda \cdot OH(0)}$$

Eq. 8

[0151] Thus

$$\lambda = \frac{\alpha}{\delta V_{Gel_max}}$$

Eq. 9

$\delta V_{i_Gel_max}$ is 2L for reference man. If $\delta V_{i_Gel_max}$ is assumed proportional to ECW_{Norm} then

$$\delta V_{i_Gel_max} = \frac{\delta_{i_Gel_max_ref}}{ECW_{Norm_ref}} \cdot ECW_{Norm} = \frac{2}{16.7} \cdot ECW_{Norm} = 0.12 \cdot ECW_{Norm}$$

Eq. 10

Relation of blood volume to interstitial volume

[0152] Under conditions of normal hydration ($OH=0$), the interstitial volume is approximately double the size of the blood volume. If this relationship is assumed to hold true for gel contraction during dehydration then from Eq. 6

$$BV(0) = \beta \cdot [V_{i_Gel_Norm} + \alpha \cdot OH(0)] = BV_{Norm} + \alpha \cdot \beta \cdot OH(0) \quad \forall OH(0) < 0$$

Eq. 11

[0153] Where β is a constant of proportionality, typically 0.5. Note that the product $\alpha \cdot \beta = k_{Guy_Norm}$. In the non-linear region of blood volume, occurring during overhydration ($OH \geq 0$), the blood volume is assumed to remain proportional to the volume of bound interstitial volume.

$$\begin{aligned} BV(0) &= BV_{Norm} + \delta BV(0) = BV_{Norm} + \beta \cdot \delta V_{i_Gel}(0) \\ &= \beta \cdot \delta V_{i_Gel_max} \cdot (1 - e^{-\lambda \cdot OH(0)}) \quad \forall OH(0) \geq 0 \end{aligned}$$

Eq. 12

[0154] The index δ indicates a deviation of a value from the corresponding value at normohydration.

Modified Guyton relationship

[0155] As BV_{Norm} corresponds with ECW_{Norm} and $ECW = ECW_{Norm} + OH$, the Guyton relationship can now be plotted via Eq. 11 and Eq. 12 as shown in Figure 8. Initial conditions of $ECW(0)$ and $BV(0)$ are shown for later explanation.

[0156] Figure 8 depicts the Guyton relationship. i.e. BV in relation to ECW

[0157] Let function f_1 be

$$f_1(OH(0)) = \alpha \cdot \beta \cdot OH(0) \quad \forall OH(0) < 0$$

Eq. 13

[0158] And let function f_2 be

$$f_2(OH(0)) = \beta \cdot \delta V_{i_Gel_max} \cdot (1 - e^{-\lambda \cdot OH(0)})$$

Eq. 14

[0159] Thus Eq. 11 and Eq. 12 can be simplified to

$$BV(0) = BV_{Norm} + f_1(OH(0)) \quad \forall OH < 0$$

Eq. 15

$$BV(0) = BV_{Norm} + f_2(OH(0)) \quad \forall OH(0) \geq 0$$

Eq. 16

Blood volume dynamics

[0160] The blood volume slope, $d(RBV)/dt$ or $\dot{R}$ is related to the difference between the refill rate, Q_{refill} and ultrafiltration rate, Q_{ufr} and the absolute blood volume BV_0 as

$$\frac{d(RBV(t))}{dt} = \frac{Q_{refill}(t) - Q_{ufr}(t)}{BV_0} = \dot{R}$$

Eq. 17

[0161] Making the assumption that the vascular refill rate, $Q_{refill}(t)$ is linearly proportional to the difference between the volume of the extracellular water ECW and the blood volume BV then

$$Q_{refill}(t) = [ECW(t) - BV(t) \cdot k_1(0)] \cdot k_r$$

Eq. 18

[0162] Where k_r is a patient specific refill constant (units of Time^{-1}) to be optimized and $k_1(0)$ is a dimensionless scaling constant as indicated on Figure 8. At initial conditions, $Q_{refill}(t^0) = 0$ and $ECW(t) = ECW(0)$ and $BV(t) = BV(0)$, thus

$$Q_{refill}(t^0) = 0 = [ECW(0) - BV(0) \cdot k_1(0)] \cdot k_r$$

Eq. 19

[0163] Therefore

$$k_1(0) = \frac{ECW(0)}{BV(0)} = \frac{ECW_{Norm} + OH(0)}{BV(0)}$$

Eq. 20

[0164] Introducing the relative blood volume, $RBV(t)$ the initial absolute blood volume, BV_0 , the normally hydrated extracellular volume ECV_{Norm} and the overhydration $OH(t)$ then Eq. 18 can be rewritten:

$$Q_{refill}(t) = [ECV_{Norm} + OH(t) - RBV(t) \cdot (ECW_{Norm} + OH(0))] \cdot k_r$$

Eq. 21

[0165] Rearranging Eq. 17 for $Q_{refill}(t)$

$$Q_{refill}(t) = \dot{R} \cdot BV_0 + Q_{UFR}(t)$$

Eq. 22

[0166] During treatment, the following relationship always holds true:

$$OH(t) = OH(0) - V_u(t)$$

$V_u(t)$ being the ultrafiltration volume at time t during treatment.

Eq. 23

[0167] Equating Eq. 21 with Eq. 22 leads to

$$\begin{aligned} \dot{R} \cdot BV_{Norm} + \dot{R} \cdot f_n(OH(0)) + Q_{UFR}(t) \\ = [ECW_{Norm} + OH(0) - V_u(t) - RBV(t) \cdot (ECW_{Norm} + OH(0))] \cdot k_r \end{aligned}$$

Eq. 24

[0168] Where the function f_n is defined as follows:

$$f_n(OH(0)) = f_1 \forall OH(0) < 0 \text{ or } f_n = f_2 \forall OH(0) \geq 0$$

Eq. 25

[0169] As a cross check, at initial conditions in steady state ($t=0^-$), $d(RBV)/dt=0$, $RBV(0)=1$, $Q_{UFR}(0)=0$, $V_u(0)=0$ and both left and right sides of Eq. 24 equate to 0 as expected. Also a special case exists at $t=0^+$ (the start of ultrafiltration) whereby Eq. 24 reduces to

$$\dot{R} \cdot BV_{Norm} + \dot{R} \cdot f_n(OH(0)) + Q_{UFR}(0^+) = 0$$

Eq. 26

[0170] Using Eq. 26, $OH(0)$ can be plotted against $d(RBV)/dt$ for different values of ultrafiltration rate $Q_{UFR}(0^+)$ which is shown in Figure 9.

[0171] I.e. in particular Figure 9 depicts a relationship between OH and $d(RBV)/dt$ for different values of $Q_{UFR}(0)$ in a reference subject with $MAT=19.4$ kg and $MLT=53.6$ kg

[0172] In Figure 9, the leftmost curve relates to an ultrafiltration rate of 1000 ml/hr, the left medium curve relates to 750 ml/hr ultrafiltration rate, the right medium curve relates to 500 ml/hr ultrafiltration rate and the rightmost curve relates to an ultrafiltration rate of 250 ml/hr.

[0173] When the vascular space is saturated (maximum blood volume) Eq. 26 is further reduced and when rearranged for the maximum rate of change of RBV , $d(RBV)/dt_{max}$ leads to:

$$\dot{R}_{max} = \frac{-Q_{ufr}}{BV_{Norm} + \beta \cdot \delta V_{i_Gel_max}} = \frac{-Q_{ufr}}{BV_{max}} \quad \forall OH \geq 0$$

Eq. 27

[0174] In Equation 27 the index max indicates respective maximum values at the beginning of the treatment.

[0175] In other words, the maximum rate of change in relative blood volume is dependent on the ultrafiltration rate and the maximum blood volume. This corresponds to the as-ymptotes implied in i.e. in particular Figure 9. It is also apparent that the upper limit of OH that can be determined is limited to ca. 3 to 7 litres (depending on the UFR), due to the high sensitivity to $d(RBV)/dt$. With a higher ultrafiltration rate the accuracy in calculating OH increases. In a patient with a low UF volume for example, a UF profile which increases UFR at the start of treatment, stepping down to lower values as treatment progresses (See Figure 10) will help to increase OH calculation accuracy and extend the upper OH range that can be determined.

[0176] I.e. as depicted in Figure 10 a stepped UF profile is proposed to allow UFR to be increased at the start of dialysis.

[0177] Eq. 26 Can be solved for OH(0) yielding

$$OH(0) = \frac{-1}{\lambda} \cdot \ln \left(\frac{Q_{ufr}(0^+) + \dot{R}(0^+) \cdot BV_{Norm}}{\dot{R}(0^+) \cdot \beta \cdot \delta V_{i_Gel_max}} \right) \quad \forall OH \geq 0$$

Eq. 28

and

$$OH(0) = \frac{-Q_{ufr}(0^+) - \dot{R} \cdot BV_{Norm}}{\dot{R} \cdot \alpha \cdot \beta} \quad \forall OH < 0$$

Eq. 29

[0178] Eq. 26 has obvious utility since the refilling constant k_r is not involved. Furthermore Eq. 26 could be primed with a known value of OH(0) from the BCM and solved for the product $\beta \cdot \delta V_{i_Gel_max}$ for some further optimization.

[0179] Eq. 24 contains two unknowns, namely the initial overhydration and the refill constant k_r . Using the BCM to obtain OH(0) as a standard, then k_r can be determined for an individual patient as a calibration. If k_r is assumed constant from treatment to treatment Eq. 24 can be solved for OH thus providing a calibrated method for determining the overhydration OH. Eq. 24 is transcendental and therefore needs to be solved numerically. Some algorithms (such as Newton-Raphson) could be derived to speed up a solution but since the likely range of OH is usually known, it would be just as easy to step through values of OH at 0.1L increments.

[0180] Another option would be to overdetermine Eq. 24, using values of RBV(t), $d(RBV)/dt$, $Vu(t)$ and $Qufr(t)$ at different time intervals allowing OH(0) and k_r to be calculated. While OH(0) is obviously single valued, k_r could be obtained during different stages of the treatment which may be of value if k_r changes over time due to treatment circumstances e.g. heat loss effects, vasoconstriction etc.

Claims

1. Apparatus (400), particularly with a memory and a digital signal processor, comprising:

a first determination unit (401) configured to determine a normalized change of a blood parameter (ΔRBV) of the individual during a treatment session;
a second determination unit (404) to determine a fluid status of the individual,
a calibration unit (406) to calibrate the determined normalized change of the blood parameter (ΔRBV) based on the fluid status, the apparatus being configured to perform a method for quantitative determination of the fluid status or a change in the fluid status comprising the following steps:

determining a first change of the blood parameter (ΔRBV) of the individual during a first treatment session (101) normalized by ultrafiltration volume and/or ultrafiltration rate of the first treatment session;

determining a first fluid status of the individual (102); and calibrating the determined first normalized change of the blood parameter (ΔRBV) based on the first fluid status (105)
determining a further change of the blood parameter during at least one further treatment session (207) normalized by ultrafiltration volume and/or ultrafiltration rate of the at least one further treatment session; and
deriving the fluid status or a change in the fluid status from the further normalized change of the blood parameter.

2. Apparatus according to claim 1, wherein the calibration unit (406) is further adapted to perform a method further comprising a step of determining a second normalized change of the blood parameter (ΔRBV) and a second fluid status during a second treatment session (103), wherein the calibration of the change of the blood parameter (ΔRBV) is based on the first and second normalized change of the blood parameter (ΔRBV) and on the first and second fluid status.
3. Apparatus according to claim 1, wherein the blood parameter is a relative blood volume (RBV) and/or the concentration of hemoglobin in the blood.
4. Apparatus according to one of the preceding claims, wherein the treatment session is a dialysis and/or ultrafiltration treatment session.
5. Apparatus, according to one of the preceding claims configured to perform a further step of approximating the change of the blood parameter (ΔRBV) by a polynomial regression (104), preferably of first order.
6. Apparatus according to claim 4, wherein calibrating comprises the determination of at least one constant C and/or a coefficient k of a polynomial.
7. Apparatus according to one of the preceding claims, wherein the fluid status is determined by an assessment of a blood composition of the individual.
8. Combination of a database and an apparatus according to one of the preceding claims, configured to perform a method wherein a first and/or second fluid status, an updated fluid status, a normal fluid status, a normohydration weight or any other data gained throughout a treatment session is transferred to the database via a data connection.
9. Combination of a database and an apparatus according to claim 8, wherein the database is operated at a central server.
10. Combination of a database and an apparatus according to claim 8 or 9 wherein the transferred data is processed such that statistics and/or conclusions for the treatment of the patient and/or a specific group of patients, in particular patients with comparable blood parameters, may be derived.
11. Apparatus according to one of the claims 1 - 7, adapted to determine the dosage of a medicament, preferably of EPO, sodium and/or iron preparations, from the fluid status and/or any other data gained throughout the treatment session.
12. Apparatus according to one of the claims 1 - 7 or 11, wherein the fluid status is determined by bioimpedance spectroscopy of the individual.
13. Computer-readable medium comprising instructions for the execution of a method for calibrating a blood parameter of an individual (100) comprising the following steps:

determining a first change of the blood parameter (ΔRBV) of the individual during a first treatment session (101) normalized by ultrafiltration volume and/or ultrafiltration rate of the first treatment session;
determining a first fluid status of the individual (102); and
calibrating the determined first normalized change of the blood parameter (ΔRBV) based on the first fluid status (105),
determining a further change of the blood parameter during at least one further treatment session (207) normalized by ultrafiltration volume and/or ultrafiltration rate of the at least one further treatment session; and
deriving the fluid status or a change in the fluid status of the individual from the further normalized change of the blood parameter when the instructions are executed on an apparatus according to any of the preceding

claims.

Patentansprüche

1. Vorrichtung (400), insbesondere mit einem Speicher und einem digitalen Signalprozessor, umfassend:

eine erste Bestimmungseinheit (401), die dafür ausgelegt ist, eine normalisierte Veränderung eines Blutparameters (ΔRBV) des Individuums während einer Behandlungssitzung zu bestimmen;
eine zweite Bestimmungseinheit (404) zum Bestimmen eines Fluidstatus des Individuums,
eine Kalibriereinheit (406) zum Kalibrieren der bestimmten normalisierten Veränderung des Blutparameters (ΔRBV) basierend auf dem Fluidstatus, wobei die Vorrichtung dafür ausgelegt ist, ein Verfahren zur quantitativen Bestimmung des Fluidstatus oder einer Veränderung des Fluidstatus durchzuführen, das die folgenden Schritte umfasst:

Bestimmen einer ersten Veränderung des Blutparameters (ΔRBV) des Individuums während einer ersten Behandlungssitzung (101), die durch das Ultrafiltrationsvolumen und/oder die Ultrafiltrationsrate der ersten Behandlungssitzung normalisiert wurde;
Bestimmen eines ersten Fluidstatus des Individuums (102); und Kalibrieren der bestimmten ersten normalisierten Veränderung des Blutparameters (ΔRBV) basierend auf dem ersten Fluidstatus (105);
Bestimmen einer weiteren Veränderung des Blutparameters während wenigstens einer weiteren Behandlungssitzung (207), die durch das Ultrafiltrationsvolumen und/oder die Ultrafiltrationsrate der wenigstens einen weiteren Behandlungssitzung normalisiert wurde; und
Ableiten des Fluidstatus oder einer Veränderung des Fluidstatus von der weiteren normalisierten Veränderung des Blutparameters.

2. Vorrichtung nach Anspruch 1, wobei die Kalibriereinheit (406) ferner dafür geeignet ist, ein Verfahren durchzuführen, das ferner einen Schritt des Bestimmens einer zweiten normalisierten Veränderung des Blutparameters (ΔRBV) und eines zweiten Fluidstatus während einer zweiten Behandlungssitzung (103) umfasst, wobei die Kalibrierung der Veränderung des Blutparameters (ΔRBV) auf der ersten und zweiten normalisierten Veränderung des Blutparameters (ΔRBV) und auf dem ersten und zweiten Fluidstatus basiert.

3. Vorrichtung nach Anspruch 1, wobei der Blutparameter ein relatives Blutvolumen (RBV) und/oder die Konzentration von Hämoglobin im Blut ist.

4. Vorrichtung nach einem der vorhergehenden Ansprüche, wobei die Behandlungssitzung eine Dialyse- und/oder Ultrafiltrations-Behandlungssitzung ist.

5. Vorrichtung nach einem der vorhergehenden Ansprüche, die dafür ausgelegt ist, einen weiteren Schritt des Näherns der Veränderung des Blutparameters (ΔRBV) durch eine polynomische Regression (104), vorzugsweise erster Ordnung, durchzuführen.

6. Vorrichtung nach Anspruch 4, wobei die Kalibrierung die Bestimmung von wenigstens einer Konstante C und/oder eines Koeffizienten k eines Polynoms umfasst.

7. Vorrichtung nach einem der vorhergehenden Ansprüche, wobei der Fluidstatus durch eine Beurteilung einer Blutzusammensetzung des Individuums bestimmt wird.

8. Kombination aus einer Datenbank und einer Vorrichtung nach einem der vorhergehenden Ansprüche, die dafür ausgelegt ist, ein Verfahren durchzuführen, wobei ein erster und/oder zweiter Fluidstatus, ein aktualisierter Fluidstatus, ein normaler Fluidstatus, ein Normohydrationsgewicht oder alle anderen Daten, die während einer Behandlungssitzung gewonnen werden, über eine Datenverbindung zu der Datenbank übertragen werden.

9. Kombination aus einer Datenbank und einer Vorrichtung nach Anspruch 8, wobei die Datenbank in einem Zentralserver betrieben wird.

10. Kombination aus einer Datenbank und einer Vorrichtung nach Anspruch 8 oder 9, wobei die übertragenen Daten verarbeitet werden, so dass eine Statistik und/oder Schlussfolgerungen für die Behandlung des Patienten und/oder

einer spezifischen Gruppe von Patienten, insbesondere Patienten mit vergleichbaren Blutparametern, abgeleitet werden können.

11. Vorrichtung nach einem der Ansprüche 1 bis 7, die dafür geeignet ist, die Dosierung eines Medikaments, vorzugsweise von EPO-, Natrium- und/oder Eisenpräparaten, aus dem Fluidstatus und/oder allen anderen Daten, die während der Behandlungssitzung gewonnen werden, zu bestimmen.

12. Vorrichtung nach einem der Ansprüche 1 bis 7 oder 11, wobei der Fluidstatus durch Bioimpedanzspektroskopie des Individuums bestimmt wird.

13. Computerlesbares Medium, umfassend Befehle für die Ausführung eines Verfahrens zum Kalibrierens eines Blutparameters eines Individuums (100), umfassend die folgenden Schritte:

Bestimmen einer ersten Veränderung des Blutparameters (Δ RBV) des Individuums während einer ersten Behandlungssitzung (101), die durch das Ultrafiltrationsvolumen und/oder die Ultrafiltrationsrate der ersten Behandlungssitzung normalisiert wird;

Bestimmen eines ersten Fluidstatus des Individuums (102); und

Kalibrieren der bestimmten ersten normalisierten Veränderung des Blutparameters (Δ RBV) basierend auf dem ersten Fluidstatus (105),

Bestimmen einer weiteren Veränderung des Blutparameters während wenigstens einer weiteren Behandlungssitzung (207), die durch das Ultrafiltrationsvolumen

und/oder die Ultrafiltrationsrate der wenigstens einen weiteren Behandlungssitzung normalisiert wurde; und

Ableiten des Fluidstatus oder einer Veränderung des Fluidstatus des Individuums von der weiteren normalisierten Veränderung des Blutparameters, wenn die Befehle in einer Vorrichtung nach einem der vorhergehenden

Ansprüche ausgeführt werden.

Revendications

1. Appareil (400), particulièrement doté d'une mémoire et d'un processeur de signaux numériques, comprenant :

une première unité de détermination (401) conçue pour déterminer un changement normalisé d'un paramètre sanguin (Δ RBV) de l'individu pendant une session de traitement ;

une seconde unité de détermination (404) pour déterminer un état de fluide de l'individu,

une unité d'étalonnage (406) pour étalonner le changement normalisé déterminé du paramètre sanguin (Δ RBV) en se basant sur l'état du fluide, cet appareil étant conçu pour réaliser un procédé de détermination quantitative de l'état du fluide ou un changement de l'état du fluide, comprenant les étapes suivantes :

la détermination d'un premier changement normalisé d'un paramètre sanguin (Δ RBV) de l'individu pendant une première session de traitement (101) normalisé par volume d'ultrafiltration/vitesse d'ultrafiltration de la première session de traitement ;

la détermination d'un premier état de fluide de l'individu (102) ; et l'étalonnage du premier changement normalisé déterminé du paramètre sanguin (Δ RBV) en se basant sur le premier état de fluide (105,)

la détermination d'un nouveau changement du paramètre sanguin pendant au moins une autre session de traitement (207) normalisé par volume d'ultrafiltration/vitesse d'ultrafiltration de l'au moins une autre session de traitement ; et

la dérivation de l'état du fluide ou d'un changement de l'état du fluide à partir de l'autre changement normalisé du paramètre sanguin.

2. Appareil selon la revendication 1, dans lequel l'unité d'étalonnage (406) est en outre apte à réaliser un procédé comprenant en outre une étape de détermination d'un second changement normalisé du paramètre sanguin (Δ RBV) et d'un second état du fluide pendant une seconde session de traitement (103), l'étalonnage du changement du paramètre sanguin (Δ RBV) étant basé sur les premier et second changements normalisés du paramètre sanguin (Δ RBV) et sur les premier et second états du fluide.

3. Appareil selon la revendication 1, dans lequel le paramètre sanguin est un volume de sang relatif (RBV) et/ou la concentration d'hémoglobine dans le sang.

4. Appareil selon une des revendications précédentes, dans lequel la cession de traitement est une session de traitement par dialyse et/ou ultrafiltration.
- 5 5. Appareil selon une des revendications précédentes, conçu pour réaliser une autre étape d'approximation du changement de paramètre sanguin (ΔRBV) par régression polynomiale (104), de préférence de premier ordre.
6. Appareil selon la revendication 4, dans lequel l'étalonnage comprend la détermination d'au moins une constante C et/ou d'un coefficient k d'une polynomiale.
- 10 7. Appareil selon une des revendications précédentes, dans lequel l'état du fluide est déterminé par évaluation d'une composition sanguine de l'individu.
8. Combinaison d'une base de données et d'un appareil selon une des revendications précédentes conçu pour réaliser un procédé dans lequel un premier et/ou second état de fluide, un état de fluide actualisé, un état de fluide normal, 15 un poids de normohydratation ou toute autre donnée obtenue pendant une session de traitement est transféré à la base de données via une connexion de données.
9. Combinaison d'une base de données et d'un appareil selon la revendication 8, dans laquelle la base de données fonctionne sur un serveur central.
- 20 10. Combinaison d'une base de données et d'un appareil selon la revendication 8 ou 9, dans laquelle les données transférées sont traitées de manière à ce que des statistiques et/ou des conclusions pour le traitement du patient et/ou un groupe spécifique de patients, en particulier des patients ayant des paramètres sanguins comparables, puissent être dérivées.
- 25 11. Appareil selon une des revendications 1 à 7, apte à déterminer le dosage d'un médicament, de préférence des préparations à base d'EPO, de sodium et/ou de fer, à partir de l'état du fluide et/ou de toute autre donnée obtenue pendant la session de traitement.
- 30 12. Appareil selon une des revendications 1 à 7 ou 11, dans lequel l'état du fluide est déterminé par spectroscopie à bioimpédance de l'individu.
- 35 13. Support lisible par ordinateur, comprenant des instructions pour l'exécution d'un procédé d'étalonnage d'un paramètre sanguin d'un individu (100), comprenant les étapes suivantes :
la détermination d'un premier changement normalisé du paramètre sanguin (ΔRBV) de l'individu pendant une première session (101) de traitement normalisé par volume d'ultrafiltration/vitesse d'ultrafiltration de la première session de traitement ;
la détermination d'un premier état de fluide de l'individu (102) ; et
40 l'étalonnage du premier changement normalisé déterminé du paramètre sanguin (ΔRBV) en se basant sur le premier état de fluide (105),
la détermination d'un nouveau changement du paramètre sanguin pendant au moins une autre session de traitement (207) normalisé par volume d'ultrafiltration/vitesse d'ultrafiltration de l'au moins une autre session de traitement ; et
45 la dérivation de l'état du fluide ou d'un changement de l'état du fluide à partir de l'autre changement normalisé du paramètre sanguin lorsque les instructions sont exécutées sur un appareil selon l'une quelconque des revendications précédentes.




Fig. 1




Fig. 2




Fig. 3




Fig. 4




Fig. 5




Fig. 6




Fig. 7




Fig. 8




Fig. 9



Fig. 10

REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Non-patent literature cited in the description

- **WIZEMANN V. et al.** The mortality risk of overhydration in haemodialysis patients. *Nephrol. Dial. Transplant*, 2009, vol. 24, 1574-1579 [0002]
- **KUHLMANN et al.** Bioimpedance, dry weight and blood pressure control: new methods and consequences. *Current Opinion in Nephrology and Hypertension*, 2005, vol. 14, 543-549 [0007]
- **CHAMNEY et al.** A new technique for establishing dry weight in hemodialysis patients via whole body bioimpedance. *Kidney Int.*, 2002, vol. 61, 2250-2258 [0008]
- **PICCOLI et al.** A new method for monitoring body fluid variation by bioimpedance analysis: the RXc graph. *Kidney Int.*, 1994, vol. 46, 534-539 [0009]
- **WEI CHEN et al.** Extracellular Water/Intracellular Water Is a Strong Predictor of Patient Survival in Incident Peritoneal Dialysis Patients. *Blood Purif.*, 2007, vol. 25, 260-266 [0010]
- **CHAMNEY P.W. ; WABEL P. ; MOISSE U.M. et al.** A whole-body model to distinguish excess fluid from the hydration of major body tissues. *Am. J. Clin. Nutr.*, 08 January 2007, vol. 5 (1), 80-9 [0011]
- **ZHU et al.** Adjustment of dry weight in hemodialysis patients using intradialytic continuous multifrequency bioimpedance of the calf. *Int. J. Artif. Organs*, 2004, vol. 12, 104-109 [0012]
- **ZHU et al.** A method for the estimation of hydration state during hemodialysis using a calf bioimpedance technique. *Physiol. Meas.*, 2008, S503-S516 [0012]
- **PETR MACHEK.** Guided optimization of fluid status in haemodialysis patients. *Nephrol Dial Transplant*, 2010, vol. 25, 538-544 [0014]
- **A.D. SINHA et al.** Relative Plasma Volume Monitoring During Hemodialysis Aids the Assessment of Dry Weight. *Hypertension*, 2010, vol. 55, 305-311 [0020]
- **GUYTON A.C. et al.** JE. Textbook of Medical Physiology. W.B. Saunders, 2000 [0021]
- **CHAMNEY PW ; WABEL P ; MOISSE UM et al.** A whole-body model to distinguish excess fluid from the hydration of major body tissues. *Am J Clin Nutr*, 2007, vol. 85, 80-89 [0141]
- ICRP. Basic anatomical and physiological data for use in radiological protection: reference values. Ann ICRP. ICRP, 2002, vol. 32, 5-265 [0141]
- **GUYTON AC.** *Medical Textbook of Physiology*, 1991 [0141]

专利名称(译)	用于监测透析的身体参数的校准		
公开(公告)号	EP2874540A1	公开(公告)日	2015-05-27
申请号	EP2013739614	申请日	2013-07-18
[标]申请(专利权)人(译)	弗雷森纽斯医疗护理德国有限责任公司		
申请(专利权)人(译)	费森尤斯医药DEUTSCHLAND GMBH		
当前申请(专利权)人(译)	费森尤斯医药DEUTSCHLAND GMBH		
[标]发明人	CHAMNEY PAUL MOISSEL ULRICH WABEL PETER		
发明人	CHAMNEY, PAUL MOISSEL, ULRICH WABEL, PETER		
IPC分类号	A61B5/053 A61M1/16 A61B5/00		
CPC分类号	A61M1/1603 A61B5/0537 A61B5/4875 A61B5/4881		
优先权	2012005286 2012-07-19 EP		
其他公开文献	EP2874540B8 EP2874540B1		
外部链接	Espacenet		

摘要(译)

公开了一种用于检测流体状态的变化或确定个体的流体状态的方法和装置。该方法包括以下步骤：在第一治疗期间确定个体的身体参数（<RBV）的变化（201）；确定个人的第一流体状态（202）；基于第一流体状态校准所确定的身体参数（<RBV）的变化（205）；在至少一个进一步的治疗期间确定个体的身体参数（<RBV）的变化（207）；并且从身体参数（<RBV）的变化得出个体的流体状态或流体状态的变化（208）。